18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil

Cancer

Volumn 83, Issue 2, 1998, Pages 245-253

  Moehler, Markus ^a   Dimitrakopoulou Strauss, Antonia ^b   Gutzler, Frank ^a   Raeth, Ulrich ^a   Strauss, Ludwig G ^b   Stremmel, Wolfgang ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

5 fluorouracil; Chemotherapy; Colorectal carcinoma; Liver metastases; Positron emission tomography; Prognosis; Survival

Indexed keywords

FLUOROURACIL; ANTIDOTE; ANTINEOPLASTIC ANTIMETABOLITE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; FOLINIC ACID; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DRUG DISTRIBUTION; HUMAN; LIVER METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; CARCINOMA; COLORECTAL TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG INTERACTION; FEMALE; LIVER; LIVER TUMOR; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PROGNOSIS; SCINTISCANNING;

AGED; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; COLORECTAL NEOPLASMS; DRUG INTERACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032527120     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980715)83:2<245::AID-CNCR7>3.0.CO;2-P     Document Type: Article

References (33)

1. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77:1241-6.
2. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994;330:1136-42.
3. Connors TA, Duncan R, Knox RJ. The chemotherapy of colon cancer. Eur J Cancer 1995;31A:1373-8.
4. Kemeny N. The systemic chemotherapy of hepatic metastases. Semin Oncol 1983;10:148-58.
5. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343:1405-10.
6. Nakamura T, Tabuchi Y, Nakae S, Ohno M, Saitoh Y. Serum carcinoembryonic antigen levels and proliferating cell nuclear antigen labelling index for patients with colorectal carcinoma: correlation with tumor progression and survival. Cancer 1996;77(Suppl 8):1741-6.
7. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104: 57-64.
8. Bosman FT. Prognostic value of pathological characteristics of colorectal cancer. Eur J Cancer 1995;31A:1216-21.
9. 18F-uracil positron emission tomography (PET). Eur J Cancer 1993;29A:1682-6.
10. Dimitrakopoulou A, Strauss LG, Clorius JH, Ostertag H, Schlag P, Heim M, et al. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 1993;34:1075-81.
11. Strauss, LG, Conti, PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-48.
12. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996;14: 700-8.
13. Ichiya Y, Kuwabara Y, Otsuka M, Tahara T, Yoshikai T, Fukumura T, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991;32:1655-60.
14. Okada J, Yoshikawa K, Imazeki K, Minoshima S, Uno K, Itami J, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991;32:686-91.
15. Vitola JV, Delbeke D, Meranze SG, Mazer MJ, Pinson CW. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 1996;78:2216-22.
16. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996;23:1409-15.
17. Nakata B, Chung YS, Nishimura S, Nishihara T, Sakurai Y, Sawada T, et al. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 1996;79:695-9.
18. 20 and F-18-fluorouracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 1998;39:465-73.
19. Brix G, Bellemann ME, Haberkorn U, Gerlach L, Lorenz WJ. Assessment of the biodistribution and metabolism of 5-fluorouracil as monitored by 18F PET and 19F MRI: a comparative animal study. Nucl Med Biol 1996;23:897-906.
20. 19F] nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res 1988;48:1680-8.
21. 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc Natl Acad Sci U S A 1990;87:492-6.
22. 18F-5-fluorodeoxyuridine in animals. Eur J Nucl Med 1983;2:258-61.
23. 18F-fluorouracil in sensitive versus resistant lymphocytic leukemia in mice. Cancer Res 1977;37:2306-8.
24. 18F-5-fluorouracil. Int J Nucl Med Biol 1982;9:25-35.
25. Semmler W, Bachert-Baumann P, Guckel F, Ermark F, Schlag P, Lorenz WJ, et al. Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Radiology 1990;174:141-5.
26. Wolf W, Albright MJ, Silver MS, Weber H, Reichert U, Sauer R. Fluorine-19-NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn Reson Imaging 1987;5:165-9.
27. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Moehler M, Oberdorfer F, et al. Prediction of therapy response using positron emission tomography (PET) and F-18-fluorouracil in patients with liver metastases from colorectal carcinoma. J Nucl Med. In press.
28. Young D, Vine E, Ghanbarpour A, Shani J, Siemsen JK, Wolf W. Metabolic and distribution studies with radiolabelled 5-fluorouracil. J Nucl Med 1982;21:1-7.
29. Lieberman LM, Wessels BW, Wiley AL, Gatley SJ, Nickles RJ Jr., Young D, et al. Fluorine-18-5-fluorouracil studies in human and animals. Int J Radiat Oncol Biol Phys 1980;6: 505-9.
30. Kissel J, Brix G, Bellemann ME, Strauss LG, Dimitrakopoulou-Strauss A, Schlag P, et al. Pharmacokinetic analysis of 5-(18F) Fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 1997;57: 3415-23.
31. 18F-labeled 5-fluorouracil of very high purity. J Lab Compds Radiopharm 1989;27:137-45.
32. Ardalan B, Chua L, Tian E, Reddy R, Sridhar K, Benedetto P, et al. A Phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991;9:625-30.
33. Pinedo HM, Peters GFJ. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;10:1653-64.